2024-06-12
On June 7, GlaxoSmithKline (GSK) announced that the FDA approved Arexvy, a recombinant respiratory syncytial virus (RSV) vaccine, to include adults aged 50-59 years who are at high risk of RSV. This is the first RSV vaccine to protect people aged 50-59 who are at high risk. Arexvy has been approved in the United States and Europe in 2023 for the prevention of lower respiratory diseases (LRTD) caused by RSV in adults 60 years of age and older.